SCHEMBL16058477

SCHEMBL16058477

Cc1cccc(-c2ccc(-c3ccn(C(=O)O)c(=O)c3C)cc2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PGR P06401 1/20 0.43
▸ DHODH Q02127 2/20 0.40
▸ HSD17B1 P14061 1/20 0.40
▸ HSD17B2 P37059 1/20 0.40
▸ MAPT P10636 2/20 0.40
▸ POLB P06746 1/20 0.39
▸ CTDSP1 Q9GZU7 1/20 0.39
▸ PPARG P37231 1/20 0.38
▸ PPARA Q07869 1/20 0.38
▸ FYN P06241 1/20 0.38
▸ CLK4 Q9HAZ1 1/20 0.38
▸ DYRK1B Q9Y463 1/20 0.38
▸ AKR1C2 P52895 1/20 0.37
▸ AKR1C1 Q04828 1/20 0.37
▸ CNR2 P34972 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ HDAC2 Q92769 1/20 0.37
▸ GRIA2 P42262 1/20 0.37
▸ GRIA4 P48058 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14975270 0.89 KDM4E (0.39) MAPTSMN1; SMN2KMT2APARP10PARP11
SCHEMBL14975255 0.87 COMT (0.42) DHODHPOLBHDAC2COMTHDAC8
SCHEMBL16057641 0.79 MKNK1 (0.48) DHODHPARP10PARP11
SCHEMBL16058367 0.77 DHODH (0.43) DHODHMAPTPPARGPPARAL3MBTL1
SCHEMBL14977095 0.76 GPR35 (0.42) —
SCHEMBL16057190 0.75 LDHA (0.43) DHODHSMN1; SMN2
SCHEMBL16057309 0.74 MCL1 (0.40) MAPTPPARGSMN1; SMN2KMT2AL3MBTL1
SCHEMBL14977412 0.71 CYP3A4 (0.43) DHODHMAPTSMN1; SMN2KMT2AL3MBTL1
SCHEMBL16057776 0.71 RARB (0.46) PPARGPPARATSHRSMN1; SMN2
SCHEMBL16057334 0.71 L3MBTL1 (0.42) MAPTTSHRKMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9828338-B2 Carbamate derivatives of lactam based N-acylethanolamine acid amidase (NAAA) inhibitors THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-11-28 — — US disclosed
US-20160068482-A1 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2016-03-10 — — US disclosed
WO-2014144836-A2 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-09-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160068482-A1 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS NAAA, FAAH, FAAH2 PGR 4322/4885DHODH 2122/4885HSD17B1 2398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback